Induction of Severe Initial Dip in Estimated Glomerular Filtration Rate by Sodium–Glucose Cotransporter 2 Inhibitors and Baseline Hemodynamics-Reference-Cited by-同舟云学术

Induction of Severe Initial Dip in Estimated Glomerular Filtration Rate by Sodium–Glucose Cotransporter 2 Inhibitors and Baseline Hemodynamics

Published:2024-08-10 Issue:8 Volume:50 Page:440-450
ISSN:1346-342X
Container-title:Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
language:en
Short-container-title:Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)

Author:

Mochida Satoshi¹,Hirashima Mayumi¹,Yamaguchi Toshio²,Saito Mikio³

Affiliation:

1. Department of Pharmacy, Kido Hospital

2. Department of Cardiovascular Medicine, Kido Hospital

3. Education and Research Center for Clinical Pharmacy Faculty of Pharmaceutical Sciences Niigata University of Pharmacy and Medical and Life Sciences

Publisher

Japanese Society of Pharmaceutical Health Care and Sciences

Link

https://www.jstage.jst.go.jp/article/jjphcs/50/8/50_440/_pdf

Reference30 articles.

1. 1)Bailey CJ, Renal glucose reabsorption inhibitors to treat diabetes, Trends Pharmacol Sci, 2011, 32, 63-71.

2. 2)Perkovic V, Jardine MJ, Neal B, Severine Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu P-L, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators, Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy, N Engl J Med, 2019, 380, 2295-2306.

3. 3)Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde A-M, Wheeler DC; DAPA-CKD Trial Committees and Investigators, Dapagliflozin in Patients with Chronic Kidney Disease, N Engl J Med, 2020, 383, 1436-1446.

4. 4)McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O’Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A-M; DAPA-HF Trial Committees and Investigators, Dapagliflozin in Patients with heart Failure and Reduced Ejection Fraction, N Engl J Med, 2019, 381, 1995-2008.

5. 5)Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Böhm M, Choi D-J, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca H-P, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde M-F, Spinar J, Squire I, Taddei S, Wanner C, Zannad F; EMPEROR-Reduced Trial Investigators, Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure, N Engl J Med, 2020, 383, 1413-1424.